

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/634,320	08/05/2003	Thazha P. Prakash	ISIS-5201	7886
32650	7590 02/23/2005		EXAMINER	
WOODCOCK WASHBURN LLP			EPPS FORD, JANET L	
ONE LIBERTY PLACE - 46TH FLOOR PHILADELPHIA, PA 19103		•	ART UNIT	PAPER NUMBER
	,		1635	
			DATE MAILED: 02/23/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Office Action Summer	10/634,320	PRAKASH ET AL.	
Office Action Summary	Examiner	Art Unit	
	Janet L. Epps-Ford, Ph.D.	1635	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ting within the statutory minimum of thirty (30) day ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on <u>05 Au</u>	igust 2003.		
	action is non-final.		
3) Since this application is in condition for allowan closed in accordance with the practice under E	•		
Disposition of Claims			
4) ☐ Claim(s) 1-75 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-75 are subject to restriction and/or expressions.	vn from consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the consequence of Replacement drawing sheet(s) including the correction	epted or b) objected to by the formula of the formula of the bytte for the formula of the formul	e 37 CFR 1.85(a).	
11)☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.	
Priority under 35 U.S.C. § 119			
a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s)			
Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da		

Application/Control Number: 10/634,320

Art Unit: 1635

Page 2

## **DETAILED ACTION**

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-32, drawn to a first and second oligomer comprising at least two nucleotides having a non-phosphorous-containing internucleoside linkage, classified in class 536, subclass 22.1.
  - II. Claims 33-34, drawn to a method of modulating gene expression, and a method of treating or preventing a disease or disorder associated with a target nucleic acid, classified in class 514, subclass 44.
  - III. Claims 35-64, drawn to a composition comprising an oligomer and at least one protein, wherein said oligomer includes at least two nucleotides having a non-phosphorous-containing internucleoside linkage, classified in class 536/24.5, or 530/350.
  - IV. Claims 65-66, drawn to a method of modulating gene expression, and a method of treating or preventing a disease or disorder associated with a target nucleic acid, classified in class 514, subclass 44.
  - V. Claims 67-73, drawn to a single stranded oligomer comprising a first and a second region that are complementary, classified in class 536, subclass 24.5.
  - VI. Claims 74-75, drawn to a method of modulating gene expression, and a method of treating or preventing a disease or disorder associated with a target nucleic acid, classified in class 514, subclass 44.

The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1635

- 2. Inventions I, III, and V are patentably distinct since each invention represents a distinct compound having a separate structure and chemical composition. Each compound requires a separate search and consideration of the prior art, and neither the prior art, nor the specification as filed, teach that they are capable of use together. Moreover, since each claimed product invention comprises a distinct chemical structure, the claimed products would be expected to produce distinct chemical and biological reactions once it is contacted with a cell (MPEP § 806.04, MPEP § 808.01).
- 3. Inventions II, IV and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are each drawn to a method, however each method comprises the use of a distinct product. The search of each method would require a distinct search and consideration of the prior art for the product used in the claimed method, and a further search for use of that product in the method set forth in the instant claims. Moreover, the individually claimed inventions are not disclosed a being capable of use together, and the claimed products, having a distinct chemical composition, would likely produce different effects in each method.
- 4. Inventions I, III, and V and II, IV and VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products of inventions I, III, and V can be

Art Unit: 1635

used in a method to screen for modulators of a gene target, this alternate method can be classified in 435/6.

- 5. Because these inventions are distinct for the reasons given above and the search required for invention I is not required for invention III, restriction for examination purposes as indicated is proper. Moreover, the search for inventions I and III are not required for the search of invention V. Additionally, the search for invention II is not required for the search of invention IV, and the search for inventions II and IV, are not required for the search of invention VI, therefore restriction for examination purposes as indicated is proper.
- 6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
- 8. This application contains claims directed to the following patentably distinct species of the claimed invention: (A) The first and second oligomers of invention I and the use of those oligomers in invention II comprise various claimed modifications, see claims 2-31. (B) The composition comprising an oligomer and a protein of invention III, and the use of said composition in invention IV, comprises wherein the oligomer encompasses various modifications as recited in claims 36-63. (C) The single stranded oligomer of invention V, and the use of said oligomer in invention VI, may comprise various modifications as recited in claims 68-72.

9. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 32-34, 35, 64-66, 67 and 73-75 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 10. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 11. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Art Unit: 1635

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Epps-Ford, Ph.D. whose telephone number is 571-272-0757. The examiner can normally be reached on Monday-Saturday, Flex Schedule.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on 571-272-0760. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-

9199.

Art Unit 1635